Transplantation Reports最新文献

{"title":"Early Detection Strategy of BK Polyomavirus Nephropathy in Patients undergoing Renal Transplant: A Single-Center Retrospective Study","authors":"Rodolfo Torres ,&nbsp;Camilo Montero ,&nbsp;Camilo Escobar ,&nbsp;Maricely Reina ,&nbsp;Andres Acevedo ,&nbsp;Nancy Yomayusa ,&nbsp;Diana Gayón ,&nbsp;Jorge Pérez","doi":"10.1016/j.tpr.2021.100077","DOIUrl":"10.1016/j.tpr.2021.100077","url":null,"abstract":"<div><h3>Introduction</h3><p>: BK polyoma virus nephropathy represents one of the non-immunological causes of renal graft loss with a cumulative incidence between 5 and 10 percent, and a graft loss rate on BK virus nephropathy patients that ranges from 30 to 90 percent depending on the nephropathy status at the time of diagnosis (1).</p></div><div><h3>Objective</h3><p>: To determine the outcomes regarding the kidney graft survival and kidney function of an early detection strategy for BK Polyomavirus nephropathy which is drawn upon urinary cytology in order to look for Decoy cells.</p></div><div><h3>Methodology</h3><p>: Descriptive, retrospective study type. Adult renal transplant recipients/patients from the Interdisciplinary Renal Transplant program of the Colombia University Clinic were included in a time period from 2012 to 2018, in whom monthly post-transplant monitoring with positive urinary cytology was performed.</p></div><div><h3>Results</h3><p>: 303 patients were transplanted in the program, 107 patients with positive urinary cytology were included, wherein, men predominated with 72% and 45 years old being the average age (IQR: 18–72). The cumulative incidence of polyomavirus nephropathy, under this early detection strategy, was 9.2%, thus preserving the graft survival at 24 months in a 100% of the patients with the management strategies employed.</p></div><div><h3>Conclusions</h3><p>: This early detection and monitoring study utilizing post-transplant urinary cytology proved to be useful for the early diagnosis of BK Polyomavirus nephropathy with a favorable impact on the graft livelihood.</p></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"6 3","pages":"Article 100077"},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.tpr.2021.100077","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41800271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New onset diabetes after kidney transplantation in Asian Americans – Is there an increased risk?","authors":"Joseph B. Lockridge MD ,&nbsp;Joseph B. Pryor MD ,&nbsp;Megan N. Stack FNP ,&nbsp;Shehzad S. Rehman MD ,&nbsp;Douglas J. Norman MD ,&nbsp;Angelo M. DeMattos MD ,&nbsp;Ali J. Olyaei PharmD","doi":"10.1016/j.tpr.2021.100080","DOIUrl":"10.1016/j.tpr.2021.100080","url":null,"abstract":"<div><h3>Summary</h3><p>New-onset diabetes after transplantation (NODAT) is increasing in frequency and creates many challenges directly impacting the patient and graft survival. Most transplant programs offer a fixed-dose prednisone taper schedule for the prevention of acute rejection following kidney transplantation. In this study, we investigated the incidence of NODAT in new kidney transplant recipients.</p></div><div><h3>Methods</h3><p>This was a retrospective, single-center study assessing rates of NODAT according to age, ethnicity, body weight, BMI, rejection, and prednisone dosing among kidney transplant recipients.</p></div><div><h3>Results</h3><p>Among non-diabetic consecutive kidney transplant recipients (<em>n</em> = 261) from 1/2014 to 12/2018, a total of 47 (18%) kidney transplant recipients developed NODAT. After adjusting for common NODAT risk factors, analysis of the population indicated that age, and corticosteroid dose in the Asian American population [adjusted for lower body weight, BMI] significantly increased the risk of NODAT. In multi-variance analysis, despite receiving lower standard doses of protocol corticosteroid daily, when adjusted for actual body weight (mg/kg/day) Asian American recipients had high incidence of NODAT compared to other ethnicity. Asian American received higher doses or corticosteroids (prednisone) than non-Asian Americans (0.14 mg/kg vs. 0.11 mg/kg) (<em>p</em> = 0.008). The overall incidence of rejection was not higher among those who developed NODAT (<em>p</em> = 0.55)</p></div><div><h3>Conclusion</h3><p>This is the first study to explore the relationship between corticosteroid dose and diabetes in Asian Americans. Asian Americans had higher rates of NODAT and received higher doses of weight-based corticosteroids. There is a possible iatrogenic, pharmacogenomic, and addressable etiology to NODAT in this population.</p></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"6 3","pages":"Article 100080"},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.tpr.2021.100080","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44206076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiological profile of patients on a single waiting list and donors for a kidney transplant in a hospital in Quito, Ecuador","authors":"Sueny Paloma Lima dos Santos ,&nbsp;Maria Lorena Arias Castro ,&nbsp;Gonzalo Javier Pullas-Tapia ,&nbsp;Jorge Washington Huertas Garzon","doi":"10.1016/j.tpr.2021.100075","DOIUrl":"10.1016/j.tpr.2021.100075","url":null,"abstract":"<div><h3>Background</h3><p>. In Ecuador, it is estimated that more than eight hundred people are on the waiting list for organ transplants. For this reason, the aim of this study is to describe the epidemiological profile of patients on the waiting list and donor for a kidney transplant.</p></div><div><h3>Methods</h3><p>. A cross-sectional retrospective study was performed on 67 patients who underwent transplants between 2012 and 2019. We included recipients of organs from both deceased and living donors. Age of patients and donors, period in which they underwent dialysis until the transplant, type of donor, cause of chronic kidney failure, comorbidities, type of dialysis, cold ischemia time, blood-type of donors and patients, compatibility, complications after transplant, delayed graft function, and immunosuppression, were studied.</p></div><div><h3>Results</h3><p>. A total of 45 patients were male, with age 46.80 ± 11.48 years old. Twenty-two were females, with age of 40.45 ± 12.9 years old. The mean age of the donor was 40.71 ± 13.28 years old. 55.2% of the etiology to develop CKD in patients was unknown. The second most prevalent were diabetic nephropathy and lupus nephritis, both of which registered 7.5%. Furthermore, 92.4% received kidneys from deceased donors, and the mean age of those recipients was 45.2 ± 13.9 years old. Conversely, only 7.6% had kidneys from living donors.</p></div><div><h3>Conclusions</h3><p>. The importance of knowing the epidemiological profile is for health strategies. It can be developed for the medical care of the most vulnerable population within this list, and try to reduce morbidity and mortality.</p></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"6 3","pages":"Article 100075"},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.tpr.2021.100075","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44667447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single center experience comparing two clinically available donor derived cell free DNA tests and review of literature","authors":"Erik Lawrence Lum ,&nbsp;Karid Nieves-Borrero ,&nbsp;Piyavadee Homkrailas ,&nbsp;Sabrina Lee ,&nbsp;Gabriel Danovitch ,&nbsp;Suphamai Bunnapradist","doi":"10.1016/j.tpr.2021.100079","DOIUrl":"10.1016/j.tpr.2021.100079","url":null,"abstract":"<div><p>The introduction of assays for donor-derived cell-free DNA into clinical transplant medicine has provided an additional method to assess allograft health. We compared the performance of two of these assays, Prospera™ and AlloSure®. A series of 15 paired-samples from individual kidney transplant recipients were tested using both Prospera™ and AlloSure® assays simultaneously. Test performances were determined using the company cutoff of &gt;1% to indicate active rejection. Additional analysis was also performed using a cutoff of 0.5%. Acute rejections were all confirmed by biopsy. There was one discordant result for 15 paired-samples when using a cutoff level of 1%, and results were concordant using a cutoff level of 0.5%. Seven biopsy were performed, six of which showed rejection. Using cutoff of 1%, Prospera™ identified 80% (4/5) of T cell-mediated rejections (TCMR) compared to 60% for AlloSure® (3/5). Both assays recognized the only case of antibody-mediated rejection. When using cutoff level of 0.5%, both assays correctly identified all cases of rejection. In this cohort, the two tests showed different sensitivities when using the validated cutoff of 1% dd-cfDNA, and the same sensitivity when using a lower cutoff of 0.5%. The result accuracy was confirmed by kidney biopsy.</p></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"6 3","pages":"Article 100079"},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.tpr.2021.100079","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44813027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare presentation of inflammatory myofibroblastic tumor in a failed renal allograft","authors":"Jeffrey Stern ,&nbsp;Jeanette Leonard ,&nbsp;Derek Jones ,&nbsp;Fang-Ming Deng ,&nbsp;Russell Berman ,&nbsp;Zoe Stewart","doi":"10.1016/j.tpr.2021.100078","DOIUrl":"10.1016/j.tpr.2021.100078","url":null,"abstract":"<div><p>Inflammatory myofibroblastic tumors (IMT) are rare, mesenchymal tumors that can occur in any anatomic location. IMTs have a variable clinical course but usually require wide surgical excision to prevent local recurrence. There have been limited case reports of IMT occurring in solid organ transplant recipients. Herein we report on a case of IMT presenting in a failed renal allograft. A 53-year-old male awaiting re-transplant presented with pain and a palpable mass in his allograft. Imaging demonstrated an infiltrative soft tissue mass encasing the renal hilum. Percutaneous biopsy demonstrated a myofibroblastic proliferation with myxoid background and no high-grade features. The tumor cells were diffusely positive for anaplastic lymphoma kinase-1 (ALK-1) and had a Ki-67 proliferation index of 10%. These findings were consistent with a diagnosis of IMT. A transplant nephrectomy was performed with wide margins to achieve an R0 resection. Pathology on the resection specimen confirmed an IMT that measured 6.5 cm x 6.3 cm. The patient has no evidence of local recurrence at 6-months follow-up and has been relisted for a second kidney transplant.</p></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"6 3","pages":"Article 100078"},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.tpr.2021.100078","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42537722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Renal transplantation against a positive crossmatch due to HLA-DP donor-specific antibodies without prior antibody removal – Case report","authors":"Yazin Marie ,&nbsp;Tim Key ,&nbsp;Ahmed Halawa","doi":"10.1016/j.tpr.2021.100076","DOIUrl":"10.1016/j.tpr.2021.100076","url":null,"abstract":"<div><p><strong>Background:</strong> Antibodies directed against donor mismatched Human Leucocyte Antigens (HLA) are known to cause antibody-mediated rejection and affect the graft survival of transplanted organs. The influence of donor-directed antibodies against the products of HLA class I and II genes in renal transplantation are well described for class I (HLA-A, B and C), but still not clear for class II notably HLA DP. The clinical effects of donor-specific antibodies (DSA) directed against HLA-DP are still controversial.</p><p><strong>Methods:</strong> We report the outcome of kidney transplants in three highly sensitised individuals with significant sensitisation with donor-directed HLA-DP antibody. These recipients were on the waiting list for 6, 14 and 4 years, respectively and had kidney transplants from donors after brain death (DBD) with positive B cell flow cytometry crossmatch (FCXM). Two cases received induction therapy with a depleting antibody (Thymoglobulin®) while the third received Alemtuzumab followed by standard immunosuppression.</p><p><strong>Results:</strong> The clinical course of these three patients were different. The first patient developed transplant glomerulopathy, but the graft is still functioning with eGFR 29 mL/min/1.73 m². The second patient did not have any adverse event with eGFR 26 mL/min/1.73 m², while the third patient had severe antibody-mediated rejection (AMR), which was treated successfully with eGFR 32 mL/min/1.73 m².</p><p><strong>Conclusion:</strong> Patients waiting for a deceased allograft with HLA-DP DSA and a positive FCXM can be transplanted successfully with depleting antibody or Alemtuzumab induction without prior antibody removal followed by standard immunosuppression.</p></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"6 3","pages":"Article 100076"},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.tpr.2021.100076","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43414080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kidney Transplantation in Kazakhstan: 10-Year Single Center Experience","authors":"Jamilya Saparbay ,&nbsp;Mels Assykbayev ,&nbsp;Saitkarim Abdugafarov ,&nbsp;Gulnur Zhakhina ,&nbsp;Zhanar Abisheva ,&nbsp;Gani Kuttymuratov","doi":"10.1016/j.tpr.2021.100073","DOIUrl":"10.1016/j.tpr.2021.100073","url":null,"abstract":"<div><h3>Background</h3><p>Kidney transplantation is considered the best available treatment option for patients with end-stage renal disease (ESRD).In the last decade, organ transplantation has been actively developing in Kazakhstan. Several transplant centers have been opened in 3 regions of Kazakhstan. Here we present the first report of 10-year experience of kidney transplantation in our center.</p></div><div><h3>Methods</h3><p>Clinical data of the 416 cases of LDKT and DDKT from 2010 to 2020 were collected from electronic records. All data were retrospectively analyzed.</p></div><div><h3>Results</h3><p>Among 416 kidney transplantations, 56 DDKT and 360 LDKT have been performed in our center from 2010 to 2020. The mean age of the recipient was 37.±12.5; 35.8 % female; 53.7% male. Chronic glomerulonephritis was the most common cause of renal failure in recipients (319 cases; 77%). The overall patient survival rates for 1, 3,5 years were 98.31 %; 97.97 %; 97.52 % respectively for kidney transplantation from a living donor and 98.18 % for all years from a deceased donor. The 1, 3, 5 and 7-year graft survival was 96.26%, 89.47%, 86.58% and 51.95% for the group from a deceased donor, while for the living donor group it was 97.46%, 96.84%, 95.96% and 92.85% respectively.</p></div><div><h3>Conclusions</h3><p>Our clinical outcomes were comparable to other transplant centers in Kazakhstan. However, the proportion of deceased donor kidney transplants and highly sensitized recipients is very low. We believe that with a highly qualified multidimensional transplant team and improved protocols of donor and recipient selection, our center can improve our results and diminish the complications after transplantation.</p></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"6 2","pages":"Article 100073"},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.tpr.2021.100073","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45278872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between history of bariatric surgery and graft rejection among solid organ transplant recipients","authors":"Claire R. Harrington ,&nbsp;Max Soghikian ,&nbsp;Dyanna Gregory ,&nbsp;Jane E. Wilcox ,&nbsp;Aneesha Shetty ,&nbsp;Mary E. Rinella ,&nbsp;Daniela P. Ladner ,&nbsp;Lisa B. VanWagner","doi":"10.1016/j.tpr.2020.100071","DOIUrl":"10.1016/j.tpr.2020.100071","url":null,"abstract":"<div><h3>Objective</h3><p>We sought to assess the potential association between history of bariatric surgery and graft rejection among solid organ transplant (SOT) recipients.</p></div><div><h3>Methods</h3><p>We conducted a single-center retrospective study of adult (age ≥18 years) SOT recipients (2000-2015) at a large tertiary care transplant network with graft rejection and bariatric surgery history according to the international classification of diseases 9^th revision. Data were analyzed using ANOVA, Chi Square, Fisher Exact tests, and logistic regression.</p></div><div><h3>Results</h3><p>Of 4363 SOT recipients, 72.6% had a history of graft rejection and 55 (1.3%) had a history of bariatric surgery. On univariate analysis, patients with graft rejection were more likely to have a history of bariatric surgery than those without organ rejection (1.5% vs. 0.7%, p=0.015). In multivariable analysis adjusted for age, transplant organ type, and history of calcineurin-based immunosuppression, there was increased odds of rejection among those with a history of bariatric surgery (Odds Ratio (OR): 3.01, 95% Confidence Interval (CI):0.98-4.46, p=0.05). However, when adjusted for body mass index at transplant, the association was attenuated (OR:3.48, CI:0.81-14.9, p=0.10).</p></div><div><h3>Conclusion</h3><p>Our single-center data indicate that the relationship between a history of bariatric surgery and graft rejection after SOT may be explained by obesity.</p></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"6 1","pages":"Article 100071"},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.tpr.2020.100071","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45341040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bivalirudin resistance during heart transplantation surgery.","authors":"Tomasz Urbanowicz,&nbsp;Anna Olasińska-Wiśniewska,&nbsp;Marcin Ligowski,&nbsp;Ewa Goszczyńska,&nbsp;Marek Jemielity","doi":"10.1016/j.tpr.2020.100072","DOIUrl":"10.1016/j.tpr.2020.100072","url":null,"abstract":"<div><h3>Introduction</h3><p>: Direct thrombin inhibitors are drugs of choice used to prevent thrombotic complications in hospitalized patients after heparin induced thrombocytopenia (HIT) diagnosis.</p></div><div><h3>Material and method</h3><p>: We present a case of bivalirudin resistance in patient undergoing heart transplantation due to dilated cardiomyopathy with confirmation of HIT. Bivalirudin was given intraoperatively as cardiopulmonary bypass circulation was applied. From initial infusion rate of 2.5 mg/kg/hour, up to 4 mg/kg/hour, due to low ACT results. The repeated ACT results were 422s, 452s and 468s on 5 minutes intervals<strong>.</strong></p></div><div><h3>Conclusion</h3><p>: Resistance to bivalirudin, though rare, can be overbeared by high bivalirudin dosing under ACT control during surgical procedures including heart transplantation.</p></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"6 1","pages":"Article 100072"},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.tpr.2020.100072","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41581975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes for Somali immigrant kidney transplant recipients in a large-volume transplant center","authors":"Kent J. Peterson ,&nbsp;Oscar K. Serrano ,&nbsp;Marjorie Odegard ,&nbsp;Steven J. Mongin ,&nbsp;Danielle Berglund ,&nbsp;David M. Vock ,&nbsp;Srinath Chinnakotla ,&nbsp;Ty B. Dunn ,&nbsp;Erik B. Finger ,&nbsp;Raja Kandaswamy ,&nbsp;Timothy L. Pruett ,&nbsp;Arthur J. Matas","doi":"10.1016/j.tpr.2020.100066","DOIUrl":"10.1016/j.tpr.2020.100066","url":null,"abstract":"<div><h3>Introduction</h3><p>Kidney transplantation (KT) demands that patients navigate a complex healthcare system and adhere to lifelong therapy and surveillance. Cultural and linguistic discordance between patients and providers has been identified as a barrier to successful KT. We studied KT outcomes and disparities among a native Somali population living in Minnesota.</p></div><div><h3>Methods</h3><p>Between 1995 and 2015, 2,385 patients underwent KT at our institution; 22 were self-designated Somali nationals. Patient and graft survival and time to first rejection were analyzed. Utilization of interpreter services was evaluated.</p></div><div><h3>Results</h3><p>Patient survival for the Somali cohort at 1 year was 100% and 95.5% at 5 years; compared to 97.2% at 1 year and 89.1% at 5 years for the Caucasian cohort (<em>p</em> = 0.40). Graft survival for the Somali cohort at 1 year was 100% and 95.5% at 5 years; for the Caucasian cohort 94.8% and 81.6% (<em>p</em> = 0.35). Rejection-free survival in the Somali cohort was 100% at 1 and 5 years, for the Caucasian cohort 86.2% and 82.1 (<em>p</em> = 0.41). Among 22 adult Somali KT recipients, 15 (68%) patients frequently utilized interpreter services in their KT-related clinical encounters.</p></div><div><h3>Conclusion</h3><p>Immigrant Somali KT recipients, appear to have comparable KT outcomes compared to a contemporaneous Caucasian cohort.</p></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"5 4","pages":"Article 100066"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.tpr.2020.100066","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"55218339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}